Related Experiment Video
Updated: Jul 5, 2025
An Optimized Single-Molecule Pull-Down Assay for Quantification of Protein Phosphorylation
Published on: June 6, 2022
Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma
Seraphine Kamayirese1, Sibaprasad Maity1, Lynne M Dieckman2
1Department of Biomedical Sciences, Creighton University, Omaha, Nebraska 68178, United States.
Abstract:
14-3-3ε is involved in various types of malignancies by increasing cell proliferation, promoting cell invasion, or inhibiting apoptosis. In cutaneous squamous cell carcinoma (cSCC), 14-3-3ε is overexpressed and mislocalized from the nucleus to the cytoplasm where it interacts with the cell division cycle 25 A (CDC25A) and suppresses apoptosis. Hence, inhibition of the 14-3-3ε-CDC25A interaction is an attractive target for promoting apoptosis in cSCC. In this work, we optimized the structure of our previously designed inhibitor of the 14-3-3ε-CDC25A interaction, pT, a phosphopeptide fragment corresponding to one of the two binding regions of CDC25A to 14-3-3ε. Starting from pT, we developed peptide analogs that bind 14-3-3ε with nanomolar affinities. Peptide analogs were designed by shortening the pT peptide and introducing modifications at position 510 of the pT(502-510) analog. Both molecular dynamics (MD) simulations and biophysical methods were used to determine peptide binding to 14-3-3ε. Shortening the pT peptide from 14 to 9 amino acid residues resulted in a peptide (pT(502-510)) that binds 14-3-3ε with a KD value of 45.2 nM. Gly to Phe substitution in position 510 of pT(502-510) led to further improvement in affinity (KD: 22.0 nM) of the peptide for 14-3-3ε. Our results suggest that the designed peptide analogs are potential candidates for inhibiting 14-3-3ε-CDC25A interactions in cSCC cells and thus inducing their apoptosis.
Insights
Researchers developed new peptide inhibitors targeting the 14-3-3ε-CDC25A interaction to promote apoptosis in cutaneous squamous cell carcinoma (cSCC). These optimized peptides show high affinity for 14-3-3ε, offering potential therapeutic strategies for cSCC.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- 14-3-3ε protein is implicated in various cancers, including cutaneous squamous cell carcinoma (cSCC).
- In cSCC, 14-3-3ε overexpression and cytoplasmic mislocalization lead to interaction with CDC25A, suppressing apoptosis.
- Inhibiting the 14-3-3ε-CDC25A interaction is a promising therapeutic strategy for cSCC.
Purpose of the Study:
- To optimize a previously designed phosphopeptide inhibitor (pT) targeting the 14-3-3ε-CDC25A interaction.
- To develop novel peptide analogs with enhanced binding affinity to 14-3-3ε.
- To evaluate the potential of these analogs as therapeutic agents for cSCC.
Main Methods:
- Peptide design and synthesis, including shortening and site-specific modifications.
- Molecular dynamics (MD) simulations to analyze peptide-protein interactions.
- Biophysical methods (e.g., measuring KD values) to determine binding affinities.
Main Results:
- A shortened peptide analog, pT(502-510), exhibited nanomolar affinity (KD: 45.2 nM) for 14-3-3ε.
- A further modified analog with a Gly to Phe substitution at position 510 demonstrated improved affinity (KD: 22.0 nM).
- These optimized peptides effectively bind to 14-3-3ε.
Conclusions:
- The designed peptide analogs are potent inhibitors of the 14-3-3ε-CDC25A interaction.
- These peptides represent potential therapeutic candidates for inducing apoptosis in cSCC cells.
- Further investigation into their efficacy in cSCC treatment is warranted.
